SCHEMBL289664

SCHEMBL289664

O=C(O)C1CCC(=O)N1c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.51
PHGDH O43175 1/20 0.47
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC6 Q9UBN7 1/20 0.41
NOTUM Q6P988 2/20 0.41
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39
HTT P42858 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
ACE P12821 2/20 0.39
ITGB1 P05556 1/20 0.39
ITGA5 P08648 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289579 1.00 P2RX7 (0.51) P2RX7PHGDHMEN1KMT2AHDAC6
SCHEMBL630463 1.00 P2RX7 (0.51) P2RX7PHGDHMEN1KMT2AHDAC6
SCHEMBL13284935 0.86 ESR1 (0.46) P2RX7PHGDHKMT2AHDAC6PTGER3
SCHEMBL28820301 0.86 P2RX7 (0.49) P2RX7PHGDHMEN1KMT2AHDAC6
SCHEMBL19974671 0.86 P2RX7 (0.49) P2RX7PHGDHMEN1KMT2AHDAC6
SCHEMBL2572998 0.85 CNR2 (0.52) P2RX7PHGDHNOTUMPTGER3PTGER2
SCHEMBL9108663 0.85 KMT2A (0.51) PHGDHMEN1KMT2APTGER3PTGER2
SCHEMBL22798990 0.85 PHGDH (0.43) P2RX7PHGDHMEN1KMT2APTGER3
SCHEMBL9106845 0.85 TDP1 (0.53) P2RX7PHGDHKMT2AHDAC6NOTUM
SCHEMBL9108668 0.85 KMT2A (0.51) PHGDHMEN1KMT2APTGER3PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
CN-118063371-A 5-Oxo pyrrolidine-2-carboxylate derivative, preparation method thereof, application in preparation of repellent and antifeedant 河南农业大学 2024-05-24 CN disclosed
US-11377443-B2 Pharmaceutical compounds CellCentric Limited (GB) 2022-07-05 US disclosed
CN-110049983-B Pharmaceutical compounds 细胞中心有限公司 2022-06-14 CN disclosed
US-20200407349-A1 PHARMACEUTICAL COMPOUNDS CellCentric Limited (GB) 2020-12-31 US disclosed
EP-3529248-B1 PHARMACEUTICAL COMPOUNDS CELLCENTRIC LTD (GB) 2020-08-19 EP disclosed
US-10696666-B2 Pharmaceutical compounds CellCentric Limited (GB) 2020-06-30 US disclosed
EP-2427429-B1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBVIE DEUTSCHLAND (DE) 2017-02-15 EP disclosed
US-9527811-B2 Carboxamide compounds and their use as calpain inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2016-12-27 US disclosed
EP-2419413-B1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL (JP) 2016-11-23 EP disclosed
US-8048907-B2 Receptor antagonists and their methods of use GLAXO GROUP LIMITED (GB) 2011-11-01 US disclosed
US-20110086879-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2011-04-14 US disclosed
WO-2010128102-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2010-11-11 WO disclosed
US-20100286146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2010-11-11 US disclosed
US-20100144829-A1 Novel Receptor Antagonists and Their Methods of Use GLAXO GROUP LIMITED 2010-06-10 US disclosed
US-7718693-B2 Receptor antagonists and their methods of use GLAXO GROUP LIMITED (GB) 2010-05-18 US disclosed
WO-2009074518-A1 COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS GLAXO GROUP LIMITED (GB) 2009-06-18 WO disclosed
EP-2049478-A1 SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE Glaxo Group Limited (GB) 2009-04-22 EP disclosed
WO-2008003697-A1 SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE GLAXO GROUP LIMITED (GB) 2008-01-10 WO disclosed
US-20080009541-A1 Novel Receptor Antagonists and Their Methods of Use GLAXO GROUP LIMITED (GB) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAPN1, CAPN2, CAPNS1 P2RX7 1852/4885PHGDH 2287/4885MEN1 4503/4885
US-20200407349-A1 PHARMACEUTICAL COMPOUNDS EP300, HDAC1, HDAC11 P2RX7 2158/4885PHGDH 2647/4885MEN1 1691/4885
US-20080009541-A1 Novel Receptor Antagonists and Their Methods of Use P2RX7, P2RX3, P2RX1 P2RX7 1/4885PHGDH 2706/4885MEN1 4860/4885
US-20100144829-A1 Novel Receptor Antagonists and Their Methods of Use P2RX7, P2RX3, P2RX1 P2RX7 1/4885PHGDH 2706/4885MEN1 4860/4885
US-20110086879-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAPN1, CAPN2, CAPNS1 P2RX7 1852/4885PHGDH 2287/4885MEN1 4503/4885
US-11377443-B2 Pharmaceutical compounds EP300, HDAC1, HDAC11 P2RX7 2158/4885PHGDH 2647/4885MEN1 1691/4885
US-10696666-B2 Pharmaceutical compounds EP300, HDAC1, HDAC11 P2RX7 2158/4885PHGDH 2647/4885MEN1 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.